A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

The response to treatment with low‐dose ara‐C was studied in 102 consecutive patients; 79 with myelodysplastic syndromes (MDS) and 23 with acute myelogenous leukaemia (AML) following MDS. The aim was to find variables that could predict the response to treatment. All patients had clinical symptoms related to cytopenia. Peripheral blood values, bone marrow morphology histology and chromosomes were analysed before the start of treatment. The median survival of the patients was 9 months and a poor survival was predicted by advanced age, low platelet counts, the presence of pseudo‐Pelger morphology and <2 chromosomal aberrations.

[1]  R. Day,et al.  The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure , 1991, British journal of haematology.

[2]  C. Helmers,et al.  Treatment of myelodysplastic syndromes with recombinant human erythropoietin , 1991, European journal of haematology.

[3]  R. Willemze,et al.  Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia , 1991, British journal of haematology.

[4]  E. Kimby,et al.  Treatment of myelodysplastic syndromes with retinoic acid and 1α‐hydroxy‐vitamin D3 in combination with low‐dose ara‐C is not superior to ara‐C alone. Results from a randomized study , 1990 .

[5]  D. Bowen,et al.  Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome , 1990, British journal of haematology.

[6]  M. Sanz,et al.  Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors , 1990, British journal of haematology.

[7]  P. Fenaux,et al.  Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly. , 1990, Leukemia.

[8]  A. Wåhlin,et al.  Reversal of myelofibrosis by hydroxyurea , 1990, European journal of haematology.

[9]  C. Aul,et al.  The role of low‐dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes , 1989, Cancer.

[10]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[11]  G. Gahrton,et al.  Therapeutic effects of low‐dose cytosine arabinoside, alpha‐interferon, 1α‐hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes , 1988, European journal of haematology.

[12]  H. Muss,et al.  Low dose Ara-C for patients with myelodysplastic syndromes. , 1988, Leukemia.

[13]  M. Cazzola,et al.  Prognostic parameters in myelodysplastic syndromes: A multiple regression analysis , 1988, European journal of haematology.

[14]  M. Oken,et al.  Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia , 1988, British journal of haematology.

[15]  B. Cheson,et al.  Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. , 1987, Seminars in oncology.

[16]  J. Hermans,et al.  Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases , 1987, British journal of haematology.

[17]  R. Bartl,et al.  Bone marrow histology in myelodysplastic syndromes. , 2009, Scandinavian journal of haematology. Supplementum.

[18]  F. Sigaux,et al.  Treatment of leukemia with low dose Ara-C: a study of 159 cases. , 1985, Haematology and blood transfusion.

[19]  G. Tricot,et al.  Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis , 1985, British journal of haematology.

[20]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[21]  F. Sigaux,et al.  Treatment of leukemia with low-dose ara-C: a study of 160 cases. , 1985, Seminars in oncology.

[22]  G. Tricot,et al.  Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes , 1984, British journal of haematology.

[23]  G. Tricot,et al.  Bone marrow histology in myelodysplastic syndromes , 1984, British journal of haematology.

[24]  D. J. Spiegelhalter,et al.  Statistical and Knowledge‐Based Approaches to Clinical Decision‐Support Systems, with an Application in Gastroenterology , 1984 .

[25]  A. Ost,et al.  A study of the reproducibility of the diagnostic criteria for acute leukaemia. , 2009, Scandinavian journal of haematology.

[26]  B. Coiffier,et al.  Dysmyelopoietic syndromes a search for prognostic factors in 193 patients , 2006, Cancer.

[27]  H. Tilly,et al.  Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? , 1983, Blood.

[28]  R. Fanin,et al.  Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. , 1983, Leukemia research.

[29]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[30]  C. Berzuini,et al.  Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes , 1982, British journal of haematology.

[31]  D. Catovsky,et al.  Histological study of the bone marrow in chronic granulocytic leukaemia in blast transformation. II. Bone marrow fibre content before and after autografting , 1981, Histopathology.

[32]  M. Baccarani,et al.  DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPY , 1979, British journal of haematology.